0001610618-24-000093.txt : 20240719 0001610618-24-000093.hdr.sgml : 20240719 20240719163859 ACCESSION NUMBER: 0001610618-24-000093 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240718 FILED AS OF DATE: 20240719 DATE AS OF CHANGE: 20240719 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tadvalkar Laura CENTRAL INDEX KEY: 0002020464 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36912 FILM NUMBER: 241128192 MAIL ADDRESS: STREET 1: CIDARA THERAPEUTICS, INC. STREET 2: 6310 NANCY RIDGE DRIVE, SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 4 1 wk-form4_1721421532.xml FORM 4 X0508 4 2024-07-18 0 0001610618 Cidara Therapeutics, Inc. CDTX 0002020464 Tadvalkar Laura 6310 NANCY RIDGE DRIVE STE 101 SAN DIEGO CA 92121 1 0 0 0 0 Stock Option (right to buy) 12.64 2024-07-18 4 A 0 2125 0 A 2034-07-17 Common Stock 2125 2125 D The shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant or (ii) the day prior to the date of the Issuer's 2025 annual meeting of stockholders. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Shane Ward, Attorney-in-Fact 2024-07-19